Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
,
(1)
,
,
,
,
(1)
,
(2)
,
,
(3)
,
,
,
,
(4)
,
(5)
,
,
,
(6)
,
(7)
,
,
,
(8)
,
(9)
,
,
,
,
1
2
3
4
5
6
7
8
9
2
3
4
5
6
7
8
9
S. Delaloge
- Function : Author
C. Courtinard
- Function : Author
E. Brain
- Function : Author
B. Asselain
- Function : Author
Thomas Bachelot
- Function : Author
- PersonId : 757054
- ORCID : 0000-0002-0866-9484
V. Dieras
- Function : Author
C. Levy
- Function : Author
W. Jacot
- Function : Author
V. Lorgis
- Function : Author
M. Ferrero
- Function : Author
L. Uwer
- Function : Author
M. Mouret-Reynier
- Function : Author
T. Petit
- Function : Author
- PersonId : 791590
- ORCID : 0000-0002-7922-9363
- IdRef : 235566365
G. Chenuc
- Function : Author
T. Guesmia
- Function : Author
M. Robain
- Function : Author
C. Cailliot
- Function : Author